Literature DB >> 11922707

Deep brain stimulation of the pedunculopontine region in the normal non-human primate.

Dipankar Nandi1, Xuguang Liu, Jonathan L Winter, Tipu Z Aziz, John F Stein.   

Abstract

Lesions in the pedunculopontine nucleus (PPN) cause akinesia. The PPN degenerates in Parkinson's disease. Stimulation of the PPN region induces stepping movements in rats and cats. These findings suggest that the PPN may play an important role in akines ia and that stimulating it may alleviate akinesia.Therefore, we have stereotactically implanted a macroelectrode in the left PPN region in a normal macaque to investigate the effects of deep brain stimulation at different frequencies. Motor activity was recorded with an infra-red counter and behaviour videotaped. At frequencies above 45 Hz there was significantly more severe akinesia than at lower frequencies (paired t -test, n=15, P<0.005). At 100 Hz, there was gross impairment of postural control. At low frequencies (5-30 Hz), stimulation induced a 5-Hz tremor in the right arm. We conclude that stimulating the PPN region at high frequency causes akinesia, whereas low frequencies induce some positive motor effects. Copyright 2002, Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 11922707     DOI: 10.1054/jocn.2001.0943

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  19 in total

Review 1.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

Review 4.  Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.

Authors:  Thomas J Feuerstein; Miriam Kammerer; Carl Hermann Lücking; Andreas Moser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

5.  Effect of globus pallidus internus stimulation on neuronal activity in the pedunculopontine tegmental nucleus in the primate model of Parkinson's disease.

Authors:  Jianyu Zhang; Zhong I Wang; Kenneth B Baker; Jerrold L Vitek
Journal:  Exp Neurol       Date:  2011-07-29       Impact factor: 5.330

6.  Deep-Brain Stimulation for Basal Ganglia Disorders.

Authors:  Thomas Wichmann; Mahlon R Delong
Journal:  Basal Ganglia       Date:  2011-07-01

Review 7.  Pedunculopontine stimulation from primate to patient.

Authors:  Erlick A C Pereira; Dipankar Nandi; Ned Jenkinson; John F Stein; Alexander L Green; Tipu Z Aziz
Journal:  J Neural Transm (Vienna)       Date:  2011-03-30       Impact factor: 3.575

8.  Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression.

Authors:  M Gomez-Gallego; E Fernandez-Villalba; A Fernandez-Barreiro; M T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2006-09-21       Impact factor: 3.575

9.  The effects of deep brain stimulation on sleep in Parkinson's disease.

Authors:  Amy W Amara; Ray L Watts; Harrison C Walker
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

10.  Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease.

Authors:  Samer D Tabbal; Mwiza Ushe; Jonathan W Mink; Fredy J Revilla; Angie R Wernle; Minna Hong; Morvarid Karimi; Joel S Perlmutter
Journal:  Exp Neurol       Date:  2008-02-14       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.